J4649

Sigma-Aldrich

JNJ-10198409

≥98% (HPLC), solid

Synonym(s):
3-Fluoro-N-(6,7-dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamine, N-(3-fluorophenyl)-2,4-dihydro-6,7-dimethoxy-Indeno[1,2-c]pyrazol-3-amine, RWJ 540973
Empirical Formula (Hill Notation):
C18H16FN3O2
CAS Number:
Molecular Weight:
325.34
PubChem Substance ID:
NACRES:
NA.77

Quality Level

assay

≥98% (HPLC)

form

solid

color

off-white

solubility

DMSO: >10 mg/mL
H2O: <2 mg/mL

originator

Johnson & Johnson

storage temp.

−20°C

SMILES string

COc1cc2Cc3c(Nc4cccc(F)c4)n[nH]c3-c2cc1OC

InChI

1S/C18H16FN3O2/c1-23-15-7-10-6-14-17(13(10)9-16(15)24-2)21-22-18(14)20-12-5-3-4-11(19)8-12/h3-5,7-9H,6H2,1-2H3,(H2,20,21,22)

InChI key

ZDNURMVOKAERHZ-UHFFFAOYSA-N

Packaging

1, 5 mg in glass bottle

Biochem/physiol Actions

JNJ-10198409 is a potent ATP-competitive inhibitor of Platelet-Derived Growth Factor receptor tyrosine kinase (PDGF-RTK) with both antiangiogenic and a direct tumor cell antiproliferative activity. It is selective for PDGF-β kinase with IC50 values of 4.2 nM for PDGF-β and 45 nM for PDGF-α kinase.

Features and Benefits

This compound is a featured product for Kinase Phosphatase Biology research. Click here to discover more featured Kinase Phosphatase Biology products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
This compound is featured on the PAF Receptor and PDGFR pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

storage_class_code

13 - Non Combustible Solids

WGK Germany

WGK 3

Flash Point F

Not applicable

Flash Point C

Not applicable

Certificate of Analysis

Certificate of Origin

Michael R D'Andrea et al.
Molecular cancer therapeutics, 4(8), 1198-1204 (2005-08-12)
With the advent of agents directed against specific molecular targets in drug discovery, it has become imperative to show a compound's cellular impact on the intended biomolecule in vivo. The objective of the present study was to determine if we...
Chih Y Ho et al.
Journal of medicinal chemistry, 48(26), 8163-8173 (2005-12-22)
A series of (6,7-dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines has been optimized to preserve both potent kinase inhibition activity against the angiogenesis target, the receptor tyrosine kinase of Platelet-Derived Growth Factor-BB (PDGF-BB), and to improve the broad tumor cell antiproliferative activity of these compounds. This...
Related Content
We offers many products related to PDGFR for your research needs.
Read More
Discover Bioactive Small Molecules for Kinase Phosphatase Biology
Read More

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service